N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change
N/A N=90 A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin
Skin Care
Primary: Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use — 3; 0…
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
Phase 2 N=30 Rosacea and Ivermectin
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants
Phase 2 N=10 Open Label Pilot Study of Apremilast in Treatment of Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
N/A N=113 To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Skin Care
Primary: Frequency of Combined Dermatologist Score — 1; 1; 51; 55 Participants
Phase 3 N=550 A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions
N/A N=133 Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
Xerosis Cutis
Primary: Change From Baseline in Overall Dry Skin Score (ODS) — -0.9; -1.2; -0.9 units on a scale
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
Phase 4 N=48 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
Acne Vulgaris
Primary: Erythema (Redness) — 0.66; 0.91; 0.55; 0.74 units on a scale
Phase 2 N=70 Treatment of Patients With Blepharitis and Facial Rosacea
Blepharitis · Meibomianitis · Dry Eye
Primary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578
Phase 4 N=171 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12 — 38.94; 40.78; -25.77; -24.82 Number of Lesions
Phase 4 N=286 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Acne Vulgaris
Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 4 N=68 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in the Global Assessment of Acne Severity (GAAS) Score by Physician — 2.8; -1.2 score on a scale
N/A N=150 A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
Skin Care
Primary: Number of Participants Determined by a Dermatologist to Have a Clinically Relevant Positive Outcome for Cutaneous Irritation After 21 Days of Product Use — 1; 0; 0…
Phase 4 N=35 Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
Acne Prone Skin
Primary: Cutaneous Tolerability Based on Visual Inspection - Erythema — 29; 33; 30; 29 participants
Phase 2 N=112 A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Seborrheic Dermatitis
Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009
Phase 4 N=162 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Facial Irritation and Cutaneous Effects — 1.5; 5.4; 3.1; 7.8 Scores on a Scale
Phase 3 N=449 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Phase 3 N=683 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea (PPR)
Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001
Phase 3 N=547 A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 29.4; 29.7; 15.9; 18.2 Lesions
Phase 3 N=688 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Phase 2 N=41 Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…